PAX5 and chronic kidney disease: Meanwhile, the KDIGO CKD-MBD guideline update of 2017 suggests that measurements of serum PTH or BSAP can be used to evaluate bone disease in CKD stages 3–5D because markedly high or low values predict underlying bone turnover stage 3 to 5 [109].